Project Grant K08CA300913
Award Date 8/20/25
Completion Date 7/31/30
Dollars Obligated $290K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- This federal Project Grant award of $456,414 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support the development and clinical evaluation of B7-H3 chimeric antigen receptor (CAR) T cells for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults. The grant, awarded to Seattle Children's Research Institute, will fund a Phase 2 clinical trial to assess the efficacy and safety of repeatedly administering the B7-H3 CAR T cells...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $290,017.00 to St. Jude Children's Research Hospital Inc. to investigate the cell state hierarchy and transcriptional/epigenetic determinants of therapy-resistant progenitor-like cells in fusion-negative rhabdomyosarcoma (FN-RMS), a type of pediatric soft tissue sarcoma. The award will support computational and experimental research approaches, including single-cell RNA sequencing,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma (liver cancer). The $470,759 award, commencing on September 1, 2025, aims to prevent CAR T-cell exhaustion and improve the antitumor activity of GPC3-CAR T-cells through the precise, on-demand control...
- This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $197,518 to The Children's Hospital of Philadelphia (CHOP) to address barriers to conducting clinical trials for patients with rare tumors. The awardee, who serves as Chair of the Children's Oncology Group (COG) Rare Tumor Disease Committee and Study Chair for three COG clinical trials, will use the funding to: Expand the availability of rare tumor clinical trials within COG,...
- The federal Project Grant award titled "HARNESSING B CELLS AFTER STEM CELL TRANSPLANT TO PRODUCE NOVEL CAR-TS" is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a total of $415,257. The project period runs from July 3, 2025 to June 30, 2027. The award aims to leverage insights into B cell tolerance mechanisms after hematopoietic stem cell transplantation to engineer less toxic, more targeted immune cells that can eradicate hematological...
- This Project Grant award of $222,432 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to St. Jude Children's Research Hospital Inc. will fund research to investigate the role of the protein Caspase-8 in cancer, anti-cancer immunity, and CAR-T cell function. The two main aims of the project are: To understand the roles of Caspase-8 in cancer cells and its influence on anti-cancer immunity, including effects on proliferation, inflammatory signaling, resistance to CAR-T...
- This Project Grant award from the National Institutes of Health's (NIH) National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $901,205 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct genome-wide studies examining how tumor immune editing in early-stage cancers leads to immune evasion and suppression. The research aims to identify key genes, pathways, and processes that are epigenetically repressed during early tumor...
- The University of Maryland, Baltimore received a $422,799 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on therapeutic targeting and biophysical characterization of chimeric antigen receptor (CAR)-mediated trogocytosis. The project aims to investigate the molecular basis of CAR-mediated trogocytosis, a mechanism of resistance to CAR T cell therapy, and explore alternative approaches to selectively inhibit this process and enhance...